Mesothelioma is a rare but deadly form of cancer: the five-year survival rate for patients diagnosed with the disease is between five and ten percent. Although aggressive surgery can help some patients with early-stage mesothelioma, ...
Feb 29, 2016
0
336
A new study suggests that significant improvements could be made in the scoring system physicians use to estimate the stage (severity) of mesothelioma, an aggressive and deadly cancer.
Feb 2, 2016
0
1
A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article in the September 2015 issue ...
Sep 8, 2015
0
12
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the ...
Apr 20, 2015
0
7
Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation ...
Dec 17, 2014
0
0
It's been called the "fifth pillar" of cancer treatment: genetically re-engineering the human immune system to recognize cancers and fight them.
Nov 6, 2014
0
0
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized ...
Sep 29, 2014
0
0
Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations ...
Jun 6, 2014
0
0
For the first time, researchers from the Perelman School of Medicine at the University of Pennsylvania have shown the predictive power of a group of overlooked lymph nodes—known as the posterior intercostal lymph nodes—that ...
Oct 28, 2013
0
0
Clinical trials are key to finding new cancer treatments, but with patient participation hovering around 5 percent, new strategies are needed to boost enrollment, particularly to study the rare cancers that have so few cases. ...
Oct 23, 2013
0
0
